National Institutes of Health
Shows the Dietary Supplement
Sulfate Combination Outperforms Prescription Drug in
Reducing Moderate to Severe Knee Pain Due To OA (Osteoarthritis)
Edgewood, MD: After five years, approximately 14 million dollars, and with the use of over a dozen Arthritis Intervention Trial (GAIT) sponsored by the National Institutes of Health and led by various clinical investigators, has released an abstract of findings in this landmark study. The double blind, placebo controlled study was designed to evaluate the efficacy of glucosamine, chondroitin sulfate, sulfate combination (all ingredients required pharmaceutical standards), and celecoxib in joint pain. The chondroitin sulfate selectedfor use in the Laboratories, Inc. The chondroitin sulfate is supplied by Bioiberica SA under an The GAIT study was designed to rigorously assess the efficacy and safety of glucosamine and chondroitin sulfate alone and in combination. The glucosamine and chondroitin sulfate used were required to meet pharmaceutical standards as GAIT was conducted under an Investigational New Drug application (see need: "1 out of 3 Americans experience joint pain from Osteoarthritis" (American
College of Rheumatology). The resulting health care cost impacted by this number is $82 billion. The study conclusion reads: "Combination glucosamine + chondroitin sulfate is effective in treating moderate to severe knee pain due to Osteoarthritis." (79.2%) (hydrochloride) chondroitin sulfate combination product on the market. is manufactured following standards practiced by the pharmaceutical industry. "We're very pleased, but not surprised by the outcome," stated Dr. Robert Henderson, President of Laboratories, Inc. and the pharmacist who literally invented the nutraceutical joint health industry by developing CosaminDS. Dr. Henderson continues, "CosaminDS is the only brand proven effective in controlled, published, U.S. studies to reduce joint pain. Now, this prestigious world renowned health research organization has released an abstract of their study. And, they selected the exact chondroitin sulfate found only in CosaminDS (US), based on its quality and purity for use in this study." David Moore, Vice President of the Consumer Products division adds, "CosaminDS has been used in other clinical trials published in medical journals. That's why it's the number one orthopedic surgeons and rheumatologists recommended brand2. This landmark study supports the findings of previous studies." CosaminDS launched in the spring of 1992. After its many competitive products have joined the sulfate combination product is equivalent to CosaminDS in To read the full text of the abstract, visit: 2 SLACK Incorporated Market Research Survey, June, 2005, July 2003, November 2001 and April 2000. Surveys conducted of Orthopedic
Surgeons & Rheumatologists relating to


Uit de laboratoriumpraktijk Analytical performance comparison of five new generation immunoassay analyzers H.A. HENDRIKS1*, W. KORTLANDT2 and W.M. VERWEIJ1 We evaluated the analytical performance of the new nation with relatively short reaction times. This is generation immunoassay analyzers (ACS:Centaur®, especially relevant in view of the goal of shortening Architect TM i 2000,

Fermacell - ibr report_english

Institut für Baubiologie Rosenheim GmbH Summary Report No. 3001-100 “Tested and recommended by the IBR” FERMACELL gypsum fibreboard Sampling carried out under the formal supervision of the Braunschweig Materials Testing Institute Employees of the agency commissioned to carry out the tests This Test Report consists of 7 pages and may only be reproduced and published in its enti

Copyright © 2010-2014 Drug Shortages pdf